IP Verse

Pharmaceutical Compositions Based On Superstructures Of Angiotensin Receptor Antagonist/Blocker (Arb) And Neutral Endopeptidase (Nep) Inhibitor - EP3067043

The patent EP3067043 was granted to Novartis on Nov 30, 2022. The application was originally filed on Nov 4, 2008 under application number EP16157767A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3067043

NOVARTIS
Application Number
EP16157767A
Filing Date
Nov 4, 2008
Status
Granted And Under Opposition
Oct 28, 2022
Grant Date
Nov 30, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 30, 2023ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSAug 30, 2023D YOUNGADMISSIBLE
STADA ARZNEIMITTELAug 29, 2023KERNEBECKADMISSIBLE
BULLE DRAug 28, 2023KUTZENBERGER WOLFF & PARTNERADMISSIBLE
DR SCHONAug 24, 2023DR SCHONADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBAug 16, 2023SONNENHAUSERADMISSIBLE

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP1410797
OPPOSITIONEP3067043
OPPOSITIONUS6294197
OPPOSITIONWO0038676
OPPOSITIONWO03059345
OPPOSITIONWO03089417
OPPOSITIONWO03090720
OPPOSITIONWO2004083192
OPPOSITIONWO2007022113
OPPOSITIONWO2007052307
OPPOSITIONWO2007056324
OPPOSITIONWO2007056546
OPPOSITIONWO2009061713
OPPOSITIONWO9749394
SEARCHUS2002098241
SEARCHUS6248729
SEARCHWO0038676
SEARCHWO2005014043
SEARCHWO2007056546

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Chapter 45: Oral Solid Dosage Forms", Anonymous, David B. Troy, Remington: The Science and Practice of Pharmacy, 20th Edition, (20000101), pages 889 - 928, ISBN 0-7817-4673-6, XP009555235-
OPPOSITION- Anonymous, "Dosage form design and manufacture ", Anonymous, Michael E. Aulton, Pharmaceutics: The Science of Dosage Form Design 2nd Edition, Churchill Livingstone, (20100101), pages 404 - 410, ISBN 978-0443055171, XP093109633-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION, Diovan® (valsartan) Tablets", Novartis Pharmaceutical Corporation, (20071101), XP093105471-
OPPOSITION- Anonymous, "Highlights of Prescribing Information for Diovan® (valsartan) Tablets", FDA, (20071101), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021283s024lbl.pdf, (20240206), XP093128227-
OPPOSITION- Anonymous, "Pharmaceutical Excipients Guide to Applications: Cellulose Derivatives", Pharmaceutical Excipients Guide to Applications: Cellulose Derivatives, Shin-Etsu Chemical Co.,Ltd, (20050201), pages 1 - 5, Pharmaceutical Excipients Guide to Applications: Cellulose Derivatives, URL: http://www.metolose.jp/e, XP093179508-
OPPOSITION- Armstrong Norman Anthony, "Tablet Manufacture", Armstrong Norman Anthony, James Swarbrick, Encyclopedia of Pharmaceutical Technology Third Edition VOLUME 1, Informa Healthcare, (20070101), pages 3653 - 3672, doi:10.1081/E-EPT-100001726, XP093109614-
OPPOSITION- Armstrong Norman Anthony, "Tablet Manufacture by Direct Compression", Armstrong Norman Anthony, James Swarbrick, Encyclopedia of Pharmaceutical Technology Third Edition VOLUME 1, Informa Healthcare, (20070101), pages 3673 - 3683, doi:10.1081/E-EPT-120003785, XP093109625-
OPPOSITION- Augsburger Larry L, Mark J. Zellhofer, "Tablet Formulation", Augsburger Larry L, Mark J. Zellhofer, James Swarbrick, Encyclopedia of Pharmaceutical Technology Third Edition VOLUME 1, informa healthcare, (20070101), pages 3641 - 3652, doi:10.1081/E-EPT-100001725, XP093109642-
OPPOSITION- Dilip M. Parikh; Ronald W. Miller; P.W.S. Heng, Anthony Yolande, Lee Chin Chiat, "Introduction; Roller Compaction Technology; Rapid Release Granulation", Dilip M. Parikh; Ronald W. Miller; P.W.S. Heng, Anthony Yolande, Lee Chin Chiat, James Swarbrick, Dilip M. Parikh, Handbook of Pharmaceutical Granulation Technology (2nd Edition), Taylor & Francis Group, LLC, (2005), page 1-6; 159-190; 407-429, ISBN 978-0-8247-2647-8-
OPPOSITION- Fda, " Entresto® ® (sacubitril and valsartan) tablets, for oral use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20210201), pages 1 - 21, HIGHLIGHTS OF PRESCRIBING INFORMATION, (20240106), XP093116405-
OPPOSITION- Fred J. Bandelin, "Chapter 3 - Compressed Tablets by Wet Granulation", Fred J. Bandelin, H.A. LIEBERMAN, L. LACHMAN AND J.B. SCHWARTZ, Pharmaceutical Dosage Forms Tablets Volume 1, US , Marcel Dekker , (19890101), vol. 1, pages 131 - 193, ISBN 978-0-8247-8044-9, XP055370821-
OPPOSITION- Garnet E. Peck, George J. Baley, Vincent E. McCurdy, Gilbert S. Banker, "Chapter 2: Tablet Formulation and Design", Garnet E. Peck, George J. Baley, Vincent E. McCurdy, Gilbert S. Banker, H.A. LIEBERMAN, L. LACHMAN AND J.B. SCHWARTZ, Pharmaceutical dosage forms. Tablets, Vol. 1 (2nd edition), New York, Marcel Dekker, (19890101), pages 75 - 130, ISBN 0-8247-8044-2, XP009553196-
OPPOSITION- "Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms", (19970801), FDA, URL: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070237.pdf, XP055253855-
OPPOSITION- "Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms", FDA, (19970801), FDA, URL: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070237.pdf, (20160229), XP055253855-
OPPOSITION- "Highlights of Prescribing Information for Diovan® (valsartan) Tablet Formulation", Novartis, (20071129), pages 1 - 13, Novartis, URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021283s024lbl.pdf, XP055253615-
OPPOSITION- Remington, "Remington, The Science and Practice of Pharmacy", Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins , (20000101), pages 656,chapter 45, 858 - 870,885,1970, ISBN 978-0-683-30647-7, XP055301025-
OPPOSITION- Singh Shailesh K, Venkatesh Naini, "Dosage Forms: Non-Parenterals", Singh Shailesh K, Venkatesh Naini, James Swarbrick, Encyclopedia of Pharmaceutical Technology Third Edition VOLUME 1, Informa healthcare, (20070101), pages 988 - 993, XP093109658-
OPPOSITION- Sven Stegemann, "Hard Gelatin Capsules Today - and Tomorrow", CAPSUGEL LIBRARY, (20020901), pages 2 - 23, CAPSUGEL LIBRARY, URL: http://www.capsugel.com/media/library/hard-gelatin-capsules-today-and-tomorrow.pdf, XP008128828-
OPPOSITION- Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel D F, Jeng A Y, Lin T H, Zheng W, Dole W P, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", Journal of clinical pharmacology, Wiley-Blackwell Publishing, Inc., US, US , (20100401), vol. 50, no. 4, doi:10.1177/0091270009343932, ISSN 1552-4604, pages 401 - 414, XP002718352
SEARCH- AULAKH ET AL, "An update on non-peptide angiotensin receptor antagonists and related RAAS modulators", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, (20070802), vol. 81, no. 8, ISSN 0024-3205, pages 615 - 639, XP022207851 [A] 1-10 * in entirety; Figs. 9, 11; page 628, esp. right column, lines 6ff *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents